Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New rapid gonorrhea test could speed up diagnosis

NCT ID NCT07569900

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study is testing a new rapid test for gonorrhea called the iStatis Gonorrhea Antigen Test. The test uses a vaginal swab and gives results quickly at the clinic. Researchers want to see how accurate and easy it is to use when performed by trained staff. About 650 women will take part, and their test results will be compared to a standard lab test.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
iStatis Gonorrhea Antigen Test (a rapid diagnostic device)
What this could lead to
If successful, this could provide a fast, reliable point-of-care test for gonorrhea, helping diagnose infections quickly and start treatment sooner.
What could go wrong
This is an early-stage diagnostic study, not a treatment trial. The test may not be accurate enough in real-world use, and results may not apply to men or other sample types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 650 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Age \> 16 years * Subject (or legally authorized representative) is willing to provide written informed consent before any study procedures * Female gender * Subject is able and willing to provide vaginal swab specimen for study procedures (3-4 swabs) * Subject can complete the required testing on the allocated testing day * Subject can speak, read, and write English * Subject's demographic information, risk factors, and symptoms are available and can be recorded on case report forms * Subject agrees to comply with study procedures and sample collection for both the investigational device and the reference method * Subject is willing to participate in the study site's standard-of-care Gonorrhea counselling and testing program and receive standard-of-care test results, as required and applicable * Subject is indicated for sexually transmitted infection testing for one or more of the following reasons: * At risk of Gonorrhea, such as recent unprotected intercourse, multiple or new partners within \< 60 days, known exposure to an infected partner, or prior STI history * Having signs and/or symptoms suggestive of Gonorrhea (e.g., urethral, vaginal, rectal, or pharyngeal discharge; dysuria; pelvic or lower-abdominal pain; sore throat; or rectal discomfort) * Undergoing routine or opportunistic STI screening, including family-planning, antenatal, or sexual-health clinic visits * Undergoing re-testing (test-of-cure) \> 7 days after completion of Gonorrhea treatment and clinically stable * Undergoing co-testing for other STIs where Gonorrhea testing is part of a broader diagnostic panel Exclusion Criteria * Subject 15 years of age or younger * Male gender * Female currently menstruating * Subject is unable or unwilling to provide informed consent * Subject is medically unstable or has psychiatric condition(s) that pose a risk or prevent study compliance * Subject is unable to provide paired samples for reference testing * Subject requires urgent antimicrobial treatment before specimen collection * Subject received systemic or topical antibiotics active against Gonorrhea within the previous 7 days * Subject used topical intravaginal or rectal antiseptics within 48 hours prior to study sampling * Previously enrolled for the same infection episode * Anatomical or clinical contraindication to study sampling (e.g., severe cervical pathology) * Recent urogenital procedure (e.g., cystoscopy, lavage) \< 72 hours before study sampling * Subject belongs to a protected group excluded by local ethics (e.g., incarcerated persons), unless explicitly approved by the EC/IRB * Any condition that, in the opinion of trained personnel or study staff, would make the participant unsuitable or unsafe for enrolment, interfere with completion of assessments, consent, or questionnaires, or bias study outcomes * Subject is participating in another interventional clinical study within 30 days that could interfere with study results

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gonorrhea infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Epicentre Health Research

    RECRUITING

    Durban, KwaZulu-Natal, 3650, South Africa

  • Epicentre Health Research (Cape Town)

    RECRUITING

    Cape Town, Western Cape, 7925, South Africa

  • Epicentre Health Research (Johannesburg)

    RECRUITING

    Johannesburg, Gauteng, 2193, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.